Vifor signs Japan deal for Ferinject
This article was originally published in Scrip
Executive Summary
Galenica subsidiary Vifor Pharma has signed an exclusive licensing agreement with Zeria Pharmaceutical for the development and commercialization of Ferinject (ferric carboxymaltose) for the treatment of iron deficiency anaemia in Japan. Vifor's US partner, Luitpold Pharmaceuticals, recently secured FDA approval for the product, known as Injectafer in the US.